Blood Cancer Journal - Table of Contents alert Volume 5 October 2015

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 5, October 2015 In this issue Review Original Articles Letters to the Editor Sign up for e-alerts Web feed Advertisement Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders.The journal has an Impact Factor of 3.467. Explore the benefits of submitting your next research article: http://bit.ly/1FpVSOx Review Top Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas M A Lunning and M R Green Blood Cancer J 2015 5: e361; 10.1038/bcj.2015.89 Abstract | Full Text Interpretation of cytogenetic results in multiple myeloma for clinical practice A M Rajan and S V Rajkumar Blood Cancer J 2015 5: e365; 10.1038/bcj.2015.92 Abstract | Full Text Original Articles Top Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 C C Bjorklund, L Lu, J Kang, P R Hagner, C G Havens, M Amatangelo, M Wang, Y Ren, S Couto, M Breider, Y Ning, A K Gandhi, T O Daniel, R Chopra, A Klippel and A G Thakurta Blood Cancer J 2015 5: e354; 10.1038/bcj.2015.66 Abstract | Full Text The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia M Díaz-Beyá, S Brunet, J Nomdedéu, A Cordeiro, M Tormo, L Escoda, J M Ribera, M Arnan, I Heras, D Gallardo, J Bargay, M P Queipo de Llano, O Salamero, J M Martí, A Sampol, C Pedro, M Hoyos, M Pratcorona, J J Castellano, M Nomdedeu, R M Risueño, J Sierra, M Monzó, A Navarro and J Esteve Blood Cancer J 2015 5: e352; 10.1038/bcj.2015.76 Abstract | Full Text Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype J E Jang, Y H Min, J Yoon, I Kim, J-H Lee, C W Jung, H-J Shin, W S Lee, J H Lee, D-S Hong, H-J Kim, H-J Kim, S Park, K-H Lee, J H Jang, J S Chung, S M Lee, J Park, S K Park, J-S Ahn, W-S Min and J-W Cheong on behalf of the Korean Society of Hematology AML/MDS Working Party Blood Cancer J 2015 5: e358; 10.1038/bcj.2015.84 Abstract | Full Text Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia G Palermo, D Maisel, M Barrett, H Smith, G Duchateau-Nguyen, T Nguyen, R-F Yeh, A Dufour, T Robak, D Dornan and M Weisser on behalf of the REACH investigators Blood Cancer J 2015 5: e353; 10.1038/bcj.2015.82 Abstract | Full Text Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy B Siontis, S Kumar, A Dispenzieri, M T Drake, M Q Lacy, F Buadi, D Dingli, P Kapoor, W Gonsalves, M A Gertz and S V Rajkumar Blood Cancer J 2015 5: e364; 10.1038/bcj.2015.87 Abstract | Full Text Romidepsin targets multiple survival signaling pathways in malignant T cells B C Valdez, J E Brammer, Y Li, D Murray, Y Liu, C Hosing, Y Nieto, R E Champlin and B S Andersson Blood Cancer J 2015 5: e357; 10.1038/bcj.2015.83 Abstract | Full Text Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma T Vu, W Gonsalves, S Kumar, A Dispenzieri, M Q Lacy, F Buadi, M A Gertz and S V Rajkumar Blood Cancer J 2015 5: e363; 10.1038/bcj.2015.91 Abstract | Full Text Letters to the Editor Top Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients F Boissard, J-J Fournié, A Quillet-Mary, L Ysebaert and M Poupot Blood Cancer J 2015 5: e355; 10.1038/bcj.2015.74 Full Text Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis D Esteban, N Tovar, R Jiménez, R Santacruz, T Baumann, MaC Pastor, A de la Riva, E Carrera, S Chaves, C Royo, A Navarro, S Rodríguez, C Ayuso, G Riu, N Creus, B Gómez, E Giné, A López-Guillermo and J Delgado Blood Cancer J 2015 5: e356; 10.1038/bcj.2015.78 Full Text Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis P Guglielmelli, G Rotunno, T Fanelli, A Pacilli, G Brogi, L Calabresi, A Pancrazzi and A M Vannucchi on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Blood Cancer J 2015 5: e360; 10.1038/bcj.2015.90 Full Text Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma C Ludwig, D S Williams, D B Bartlett, S J Essex, G McNee, J W Allwood, E Jewell, A Barkhuisen, H Parry, S Anandram, P Nicolson, C Gardener, F Seymour, S Basu, W B Dunn, P A H Moss, G Pratt and D A Tennant Blood Cancer J 2015 5: e359; 10.1038/bcj.2015.85 Full Text Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma H Saito, D Maruyama, A M Maeshima, S Makita, H Kitahara, K Miyamoto, S Fukuhara, W Munakata, T Suzuki, Y Kobayashi, H Taniguchi and K Tobinai Blood Cancer J 2015 5: e362; 10.1038/bcj.2015.86 Full Text Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib A Zhou, E M Knoche, E K Engle, D A C Fisher and S T Oh Blood Cancer J 2015 5: e351; 10.1038/bcj.2015.77 Full Text Advertisement Nature Publishing Group offers a free open access funding support service to enable authors to discover and apply for article processing charge funding available to them. Visit our website for further advice on the funding options available, and guidance in approaching funders and institutions, or email openaccess@nature.com for more information.  You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.